Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 2/3 1

Status

Completed 11Recruiting 5Active not recruiting 5Terminated 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 4Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Non-Small Cell Lung Cancer With HER2- Mutations 1Melanoma 1Lung Neoplasms 1First-line Advanced NSCLC Patients 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × CP protocol × Clear all
NCT05061550 2026-05-22

NeoCOAST-2

AstraZeneca

Phase 2 Recruiting
630 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07365319 2026-05-20

TeLuRide-008

Eikon Therapeutics

Phase 2/3 Recruiting
750 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06430437 2026-01-21

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
300 enrolled
Thoracic

Non-Small Cell Lung Cancer With HER2- Mutations

NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 2 Recruiting
240 enrolled
Thoracic

First-line Advanced NSCLC Patients

NCT06008106 2024-06-28

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

Shanghai Kechow Pharma, Inc.

Phase 3 Recruiting
165 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡